Clinical Development Stocks List

Clinical Development Stocks Recent News

Date Stock Title
May 10 GH Guardant Health Inc (GH) Reports Strong Q1 2024 Earnings, Surpasses Revenue Estimates
May 10 REGN Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
May 10 GH Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript
May 10 REGN Q1 2024 Intellia Therapeutics Inc Earnings Call
May 9 SRPT HHS panel to vote in Nov. on DMD screening for newborns
May 9 GH Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
May 9 GH Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
May 9 GH Guardant Health Non-GAAP EPS of -$0.46 beats by $0.27, revenue of $168.5M beats by $18.43M
May 9 GH Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
May 9 NBIX How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
May 9 NBIX Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
May 9 NBIX Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
May 9 REGN Regeneron’s gene therapy triumphs twice, restoring hearing in children
May 9 ICLR ICON releases its ICON Cares 2023 Report
May 8 GH Guardant Health Q1 2024 Earnings Preview
May 8 NBIX Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
May 8 REGN Regeneron gene therapy improves hearing in child deafness
May 8 REGN Regeneron gene therapy improves hearing in two children
May 8 REGN Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
May 7 NBIX Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
Clinical Development

Clinical development is the process of developing a new drug, medical device, or diagnostic test from the initial concept to the point of regulatory approval. It involves a series of steps, including preclinical research, clinical trials, regulatory review, and post-marketing surveillance. The goal of clinical development is to demonstrate the safety and efficacy of a product in order to obtain regulatory approval for marketing.

Browse All Tags